imuveo

Introducing imuveo

imuveo is a biotech startup developing innovative sdAb-based imaging tracers to monitor immune responses in cancer patients. Their vision is to enable oncologists to make earlier and more precise treatment decisions in immunotherapy. The founding team – Dr. Dario Gosmann, Dr. Lisa Russelli, and Dr. Paul Klein – combines many years of experience in translational immunology, radiopharmaceutical development, and entrepreneurship.

The Product imuveo is offering:

"Our lead product is a CD2-targeted PET tracer that allows real-time visualization of T-cell responses during immunotherapy. CD2 is expressed on all major T-cell subsets, including activated cells, making it an ideal marker to capture functional immune activity. With our approach, oncologists can distinguish responders from non-responders within weeks instead of waiting months for conventional imaging readouts. The tracer is rapidly cleared, does not impair T-cell function, and provides sensitive and specific insights where CT, MRI, or FDG-PET often fall short."

Their entry point when joining TUM Venture Lab Healthcare:

"When we joined TUM Venture Lab Healthcare, we had completed proof of concept for our CD2-sdAb tracer. The next critical steps were to ensure safety, establish GMP-compliant production, and prepare for our planned phase I clinical trial."

Looking back: How TUM Venture Lab Healthcare was able to support imuveo in the past:

"TUM Venture Lab Healthcare has provided crucial guidance, from refining our market fit to connecting us with investors and industry experts. The feedback and sparring we received on our pitch materials were especially valuable, helping us to better articulate our value proposition to pharmaceutical partners and VCs."

imuveo's key advice for Founders:

"Make it a habit to talk to as many people as possible – whether at conferences, networking events, or casual social gatherings. Put yourself out there, listen to their stories, and learn about their backgrounds. Every conversation not only expands your network, but you also never know when a seemingly small connection might turn into an important opportunity down the road."